No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
IGMS IGM Biosciences
- 9.860
- +0.430+4.56%
Trading May 3 15:24 ET
581.28MMarket Cap-2093P/E (TTM)
10.190High9.720Low127.97KVolume9.730Open9.430Pre Close1.27MTurnover1.08%Turnover RatioLossP/E (Static)58.95MShares17.70052wk High2.86P/B116.37MFloat Cap3.81052wk Low--Dividend TTM11.80MShs Float133.000Historical High--Div YieldTTM4.98%Amplitude3.810Historical Low9.955Avg Price1Lot Size
Intraday
- 5D
- 1D
- 1W
- 1M
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Stifel Nicolaus Sticks to Its Buy Rating for IGM Biosciences (IGMS)
IGM Biosciences Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
IGM Biosciences Price Target Maintained With a $12.00/Share by HC Wainwright & Co.
HC Wainwright & Co. Reiterates Neutral on IGM Biosciences, Maintains $12 Price Target
HC Wainwright & Co. analyst Robert Burns reiterates IGM Biosciences with a Neutral and maintains $12 price target.
Analysts' Opinions Are Mixed on These Healthcare Stocks: IGM Biosciences (IGMS) and Argenx Se (ARGX)
Why IGM Biosciences Is Rising In Pre-market?
IGM Biosciences Announces Worldwide Collaboration Agreement With Sanofi To Create And Develop IgM Agonist Antibodies Will Focus Exclusively On Immunology/Inflammation Targets
IGM Biosciences Announces Worldwide Collaboration Agreement With Sanofi To Create And Develop IgM Agonist Antibodies Will Focus Exclusively On Immunology/Inflammation Targets
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg